sFlt-1 functions as an antiangiogenic agent by binding to circulating free PlGF, causing a substantial reduction in blood PlGF concentration in preeclampsia compared to that in normal pregnancies [6,7]. The gene discussed is PGF; the disease is preeclampsia.